Chitosan-based Targeting Drug Delivery Systems (Cs-tDDS) and their Proof of Concept

Today, the most efficient therapeutic approaches in cancer rely on targeting the tumoral cells in order to enhance the therapeutic effect of the drug, to decrease its dosage and to limit its side effects. The TARGETUM Project aims at building a new class of Chitosan-based targeting Drug Delivery Systems(CstDDS) able to selectively anchor mediators of endothelial cells surface that are involved in the tumor angiogenic process and providing an in vivo Proof of Concept of a promising Cs- tDDS candidate that demonstrates safety and efficacy.

Consortium

Companies: Kitozyme, UCB

Research centers: ULg and UCL

Contact Audrey DESCHAMPS ([email protected]) KITOZYME SA

Website: www.kitozyme.com

Image